Gyre Therapeutics (GYRE) to Release Earnings on Tuesday

Key Points

• Gyre Therapeutics (NASDAQ:GYRE) is expected to announce its Q2 2025 earnings on August 12th, with anticipated earnings of $0.03 per share and revenue of $30.80 million.
• The company's previous earnings report indicated that Gyre achieved $0.03 EPS, matching consensus estimates, but revenue fell short at $22.06 million compared to an expected $28.40 million.
• Bank of America Corp DE increased its stake in Gyre Therapeutics by 40.4% recently, indicating growing institutional interest in the company.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Gyre Therapeutics to post earnings of $0.03 per share and revenue of $30.80 million for the quarter.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.03. The firm had revenue of $22.06 million for the quarter, compared to analysts' expectations of $28.40 million. Gyre Therapeutics had a net margin of 7.20% and a return on equity of 9.73%.

Gyre Therapeutics Trading Down 0.3%

NASDAQ:GYRE traded down $0.03 during trading hours on Friday, reaching $7.18. 23,874 shares of the company were exchanged, compared to its average volume of 169,387. The firm has a market cap of $672.73 million, a PE ratio of 359.18 and a beta of 1.80. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $19.00. The stock's 50-day moving average is $7.73 and its 200-day moving average is $9.28.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Gyre Therapeutics stock. Bank of America Corp DE raised its position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 40.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,937 shares of the company's stock after acquiring an additional 1,996 shares during the quarter. Bank of America Corp DE's holdings in Gyre Therapeutics were worth $84,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.